Luxcel Biosciences Announces World First Physiologically Relevant, In Vitro Ischemia-Reperfusion Model In Conjunction With BMG LABTECH GmbH And Ncardia

Published: Sep 26, 2017

CORK, Ireland, Sept. 26, 2017 /PRNewswire/ -- Ischemia-reperfusion (IR) injury, occurs in the body when blood supply returns to tissues after a period of oxygen and nutrient deprivation. It is an important feature of several diseases including cardiac arrest, stroke and cancer, and is a critical consideration during transplantation. While significant advances have been made in understanding IR injury, progress has been impaired by i. the absence of a method to accurately and reproducibly replicate injury conditions in vitro, and ii. tools have not been available to quantitatively measure real-time cellular oxygenation in the ischemic cells.

These barriers to better understanding and treating IR injury have now been overcome, with the ground-breaking development of the first microplate-based in vitro Ischemia-Reperfusion Model. This advance is made possible by combining three innovative new technologies: i. BMG LABTECH's CLARIOstar® microtitre plate reader, with Atmoshpheric Control Unit (ACU) and rapid gas ramping function, ii. Luxcel Biosciences' unique MitoXpress® Intra Intracellular Oxygen Concentration Assay, allowing real-time quantitation of cellular oxygenation, and iii. Ncardia's iPSC-derived human Cor.4U® cardiomyocyte cells. This powerful new in vitro model will enable researchers and drug discovery scientists to better replicate and understand the biology of IR injury facilitating the development of more effective therapeutic interventions.

"We are really excited about this innovative new tool for the ischemia reperfusion field, made possible by our recently reported MetaCell-TM collaboration, supported by the EU H2020 fast track to innovation initiative.  The CLARIOstar® has integrated software for the MitoXpress® Intra assay, allowing scientists to consistently and accurately quantify the oxygen concentration within the cells as they experience rapid de-and re-oxygenation, and see this happening in real-time.  We believe this model has the potential to revolutionise the approach researchers in cell biology and drug safety toxicity can take to evaluate ischemic reperfusion and to reduce the dependency for in vivo animal models," Dr. Ian Hayes, Commercial Director Luxcel Biosciences Ltd.  

Contact Alanna +353 86 2741539

About Luxcel Biosciences Ltd

Luxcel Biosciences Ltd was founded in 2002 in Co. Cork, Ireland, and is a multi-award winning provider of cost effective and easy to use real-time kinetic fluorescence-based in vitro live-cell test kits, targeting Cell Metabolism, Drug Safety and Toxicity, and Hypoxia and Oxidative Stress applications.  Our customers range from University research scientists, to global Pharmaceutical Companies and Contract Research Organisations.  Pfizer Inc., one of the world's largest pharmaceutical companies, is a key collaborator in the field of drug safety and mitochondrial toxicity screening. Several joint research publications in high impact journals have resulted from this successful collaboration.

For more information visit our new website


BMG LABTECH is at the forefront of technology offering high-quality and reliable microplate readers for life sciences applications and high-throughput screening. The company is on a steady course of growth due to continuous development of innovative and unique technologies over the past 25 years.  BMG LABTECH offers a worldwide sales and support network, with offices in the USA, UK, Australia, Japan and France.  More than 50 distributors provide additional product, technical and software support all over the world.

For more information visit

About Ncardia
Ncardia is a stem cell drug discovery & development company operating worldwide with facilities and offices in Belgium, The Netherlands, Germany and the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis. The Ncardia goal is to be the supportive and trusted partner for scientists operating in the hiPSC drug discovery and development space including cardiovascular and neural safety and efficacy studies.

For more information visit

About MetaCell

The MetaCell-TM project H2020 FTI 2.5m funding enables the consortium of Luxcel Biosciences Ltd, Axiogenesis AG (now Ncardia and BMG LABTECH GmbH to develop a physiologically relevant cell-based assay platform for metabolism in preclinical drug discovery and development, creating the Gold Standard, within a laboratory in vitro setting. This project is supported by two highly respected research institutions, Oxford University, UK and Imperial College London, UK.

For more information visit

View original content with multimedia:

SOURCE Luxcel Biosciences Ltd

Back to news